Predicting the presence of coronary plaques featuring high-risk characteristics using polygenic risk scores and targeted proteomics in patients with suspected coronary artery disease

Peter Loof Møller,Palle Duun Rohde,Jonathan Nørtoft Dahl,Laust Dupont Rasmussen,Louise Nissen,Samuel Emil Schmidt,Victoria McGilligan,Daniel F. Gudbjartsson,Kari Stefansson,Hilma Holm,Jacob Fog Bentzon,Morten Bøttcher,Simon Winther,Mette Nyegaard
DOI: https://doi.org/10.1186/s13073-024-01313-8
IF: 15.266
2024-03-22
Genome Medicine
Abstract:The presence of coronary plaques with high-risk characteristics is strongly associated with adverse cardiac events beyond the identification of coronary stenosis. Testing by coronary computed tomography angiography (CCTA) enables the identification of high-risk plaques (HRP). Referral for CCTA is presently based on pre-test probability estimates including clinical risk factors (CRFs); however, proteomics and/or genetic information could potentially improve patient selection for CCTA and, hence, identification of HRP. We aimed to (1) identify proteomic and genetic features associated with HRP presence and (2) investigate the effect of combining CRFs, proteomics, and genetics to predict HRP presence.
genetics & heredity
What problem does this paper attempt to address?
The paper primarily explores how to predict the presence of High-Risk Coronary Plaque (HRP) in patients suspected of having Coronary Artery Disease (CAD) by combining Clinical Risk Factors (CRFs), proteomics data, and genetic information. The researchers aim to address the following two key questions: 1. **Identify proteomic and genetic features associated with HRP**: By analyzing the proteomics data and genetic information of patients, identify biomarkers associated with HRP. 2. **Evaluate the effectiveness of combining CRFs, proteomics, and genetic information in predicting the presence of HRP**: Investigate whether integrating these different types of biomedical information can improve the accuracy of predicting the presence of HRP. The study found that combining genetic data with clinical or proteomics data can improve the prediction of HRP presence in patients suspected of CAD. Particularly for patients younger than 55 years old, this combination significantly enhances prediction accuracy. However, adding proteomics data alone to the clinical risk factors model did not significantly improve the prediction results. This finding suggests that genetic data can provide additional information for the presence of HRP, especially in younger patients.